Published in Early Hum Dev on February 01, 2011
Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials. Pediatr Infect Dis J (2014) 0.81
The use of antifungal therapy in neonatal intensive care. Clin Perinatol (2012) 0.76
First dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole. Clin Pharmacokinet (2014) 0.75
Cryptococcal Meningitis Presenting as a Complication in HIV-infected Children: A Case Series From Sub-Saharan Africa. Pediatr Infect Dis J (2016) 0.75
Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med (2002) 9.21
A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med (1994) 9.11
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis (1991) 6.43
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis (2002) 6.13
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 4.17
Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics (2006) 3.78
Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother (2002) 3.40
Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis (2010) 3.26
Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother (2003) 3.03
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos (2003) 2.91
Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother (2006) 2.89
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84
Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr (1988) 2.62
Adverse reactions to voriconazole. Clin Infect Dis (2004) 2.51
Flucytosine. Ann Intern Med (1977) 2.14
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother (2004) 2.08
Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother (2001) 2.03
In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother (1998) 1.98
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol (2003) 1.82
Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother (2008) 1.79
Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother (2008) 1.68
New targets and delivery systems for antifungal therapy. Med Mycol (2000) 1.65
Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med (1987) 1.65
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer (2007) 1.65
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis (2004) 1.64
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis (2008) 1.62
Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly (2006) 1.61
Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother (2005) 1.59
Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol (2002) 1.58
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother (2006) 1.55
Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet (1997) 1.54
Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol (2004) 1.53
Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis (1996) 1.43
The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J (2006) 1.36
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther (2004) 1.35
Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother (2001) 1.34
Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J (2009) 1.33
Prevalence of Candida species in hospital-acquired urinary tract infections in a neonatal intensive care unit. Pediatr Infect Dis J (1997) 1.27
Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob Agents Chemother (1998) 1.24
Clinical use of systemic antifungal agents. Clin Pharm (1988) 1.23
Pharmacokinetics of amphotericin B in infants and children. J Infect Dis (1987) 1.21
Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob Agents Chemother (1991) 1.19
Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother (2005) 1.13
Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy (2001) 1.13
A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant (2006) 1.12
Investigational antifungal agents. Pharmacotherapy (2001) 1.11
Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr (1990) 1.11
Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis (1994) 1.11
Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother (2008) 1.11
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother (2008) 1.08
Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother (1989) 1.07
Voriconazole: a new triazole antifungal. Ann Pharmacother (2000) 1.06
Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J (2007) 1.05
Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother (2008) 1.04
Antifungal agents. Part I. Amphotericin B preparations and flucytosine. Mayo Clin Proc (1998) 1.04
Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol Pharm Bull (2006) 1.00
Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother (2006) 0.97
Population pharmacokinetics of amphotericin B in children with malignant diseases. Br J Clin Pharmacol (2001) 0.97
Voriconazole plasma monitoring. Arch Dis Child (2008) 0.92
The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial. Ann Surg (2009) 0.91
In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother (2000) 0.91
Hepatotoxicity of antifungal agents. Curr Opin Investig Drugs (2005) 0.90
Agents for treatment of invasive fungal infections. Otolaryngol Clin North Am (2000) 0.90
Penetration of ravuconazole, a new triazole antifungal, into rat tissues. Chemotherapy (2002) 0.89
Intravenous voriconazole therapy in a preterm infant. Pharmacotherapy (2005) 0.88
Flucytosine. An effective oral treatment for chromomycosis. Arch Dermatol (1974) 0.87
Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses (1997) 0.86
Antifungal agents--clinical pharmacokinetics and drug interactions. Mycoses (2008) 0.83
Ravuconazole Eisai/Bristol-Myers Squibb. Curr Opin Investig Drugs (2002) 0.83
Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection. Pediatr Infect Dis J (2003) 0.83
Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy (2009) 0.82
Amphotericin B serum levels in pediatric bone marrow transplant recipients. Bone Marrow Transplant (1991) 0.81
A randomized, controlled trial of parenteral clindamycin in neonatal necrotizing enterocolitis. J Pediatr (1988) 0.80
Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. Int J Antimicrob Agents (2010) 0.79
A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates. Int J Pharm (2002) 0.78
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Sports medicine and ethics. Am J Bioeth (2013) 5.51
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis (2013) 4.07
Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis (2006) 3.70
Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics (2009) 3.05
Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. Pediatrics (2010) 2.48
Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell (2006) 2.35
Economic return of clinical trials performed under the pediatric exclusivity program. JAMA (2007) 2.28
Early predictors of in-hospital death in infective endocarditis. Circulation (2004) 2.26
Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol (2014) 2.11
The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics (2006) 2.10
Contemporary Fontan operation: association between early outcome and type of cavopulmonary connection. Ann Thorac Surg (2012) 2.04
Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation (2010) 2.01
Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? Pediatrics (2006) 1.98
Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis (2005) 1.92
Early and late onset sepsis in late preterm infants. Pediatr Infect Dis J (2009) 1.90
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremia. Crit Care Med (2008) 1.69
Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol (2011) 1.64
Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis (2012) 1.63
Use of the complete blood cell count in late-onset neonatal sepsis. Pediatr Infect Dis J (2012) 1.63
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis (2008) 1.62
Traumatic lumbar punctures in neonates: test performance of the cerebrospinal fluid white blood cell count. Pediatr Infect Dis J (2008) 1.55
Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J (2012) 1.53
No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants. Pediatr Infect Dis J (2015) 1.53
In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother (2004) 1.44
Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis (2006) 1.36
Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J (2005) 1.33
Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J (2009) 1.33
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J (2011) 1.30
Value of an inhalational model of invasive aspergillosis. Med Mycol (2004) 1.29
Orbital cellulitis in children. Pediatr Infect Dis J (2006) 1.27
Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother (2012) 1.23
Neurodevelopmental outcome of extremely low birth weight infants with Candida infection. J Pediatr (2013) 1.22
Major infection after pediatric cardiac surgery: a risk estimation model. Ann Thorac Surg (2010) 1.21
Quantification of 1,3-beta-D-glucan levels in children: preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol (2007) 1.20
Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J (2009) 1.20
Obesity, inflammation, and asthma severity in childhood: data from the National Health and Nutrition Examination Survey 2001-2004. Ann Allergy Asthma Immunol (2009) 1.19
Coagulase-negative staphylococcal infections in the neonatal intensive care unit. Infect Control Hosp Epidemiol (2011) 1.19
AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol Ther (2008) 1.18
Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J (2011) 1.14
Pediatric cardiovascular drug trials, lessons learned. J Cardiovasc Pharmacol (2011) 1.13
Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J (2012) 1.09
Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. Pediatr Infect Dis J (2009) 1.09
Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics (2014) 1.08
In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos (2010) 1.08
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. Antimicrob Agents Chemother (2004) 1.08
A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect (2004) 1.08
Use of the complete blood cell count in early-onset neonatal sepsis. Pediatr Infect Dis J (2012) 1.07
Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother (2010) 1.06
Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J (2013) 1.06
Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J (2007) 1.05
A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV. AIDS (2003) 1.05
Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics (2008) 1.05
Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. Ther Drug Monit (2012) 1.04
Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia. J Lab Clin Med (2004) 1.03
Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. J Pediatr (2012) 1.02
Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J (2013) 1.02
Meningitis in preterm neonates: importance of cerebrospinal fluid parameters. Am J Perinatol (2008) 1.01
Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. Antimicrob Agents Chemother (2014) 1.01
Criteria supporting the study of drugs in the newborn. Clin Ther (2006) 1.00
Pediatric residents' clinical diagnostic accuracy of otitis media. Pediatrics (2002) 1.00
Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. Mol Ther (2006) 0.99
Center variation in patient age and weight at Fontan operation and impact on postoperative outcomes. Ann Thorac Surg (2011) 0.98
In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats. Drug Metab Dispos (2010) 0.98
Excess costs of hospital care associated with neonatal candidemia. Pediatr Infect Dis J (2007) 0.97
Nosocomial infection in the NICU: a medical complication or unavoidable problem? J Perinatol (2004) 0.96
Total lymphocyte count and World Health Organization pediatric clinical stage as markers to assess need to initiate antiretroviral therapy among human immunodeficiency virus-infected children in Moshi, Northern Tanzania. Pediatr Infect Dis J (2009) 0.95
Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos (2008) 0.95
Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control (2010) 0.95
Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr Infect Dis J (2012) 0.95
Prevention and treatment of nosocomial sepsis in the NICU. J Perinatol (2004) 0.93
Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm Drug Dispos (2011) 0.93
Effect of sex and race on outcome in patients undergoing congenital heart surgery: an analysis of the society of thoracic surgeons congenital heart surgery database. Ann Thorac Surg (2012) 0.93
Neonatal candidiasis. Infect Dis Clin North Am (2005) 0.91
The economic returns of pediatric clinical trials of antihypertensive drugs. Am Heart J (2008) 0.91
Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J (2012) 0.90
Effect of methicillin-resistant Staphylococcus aureus colonization in the neonatal intensive care unit on total hospital cost. Infect Control Hosp Epidemiol (2009) 0.90
Examination of type IV pilus expression and pilus-associated phenotypes in Kingella kingae clinical isolates. Infect Immun (2010) 0.89
Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation (2004) 0.89
Early sepsis does not increase the risk of late sepsis in very low birth weight neonates. J Pediatr (2013) 0.88
Risk factors and prevention of late-onset sepsis in premature infants. Early Hum Dev (2010) 0.88